Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer

IRVINE, Calif. & AMSTERDAM & RYE BROOK, N.Y.-- --Agendia, a leading molecular diagnostics company, and CBLPath, Inc., a leading pathology services provider, today announced they have agreed to collaborate in providing molecular diagnostics testing to breast cancer patients.



via Rye Brook Newswire http://ift.tt/1snO5M8